In This Article
- Health care professionals at this year's #AHA18 talked research, treatment approaches and guidelines on the podium and in conference halls
- These conversations continued on Twitter, with thousands of #AHA18 tweets
- Highlights include the updated cholesterol guidelines, PIONEER-HF and REDUCE-IT
Health care professionals at this year’s American Heart Association's Scientific Sessions discussed late-breaking research, innovative treatment approaches and new patient care guidelines. The conversations carried over from the podium and conference halls onto Twitter, with thousands of tweets, according to Symplur. Trending topics included the updated cholesterol guidelines and outcomes of both the REDUCE-IT and PIONEER-HF trials.
Subscribe to the latest updates from Cardiovascular Advances in Motion
Here is a list of some noteworthy #AHA18 tweets.
New Cholesterol Guidelines
Pradeep Natarajan, MD, MMSc, director of Preventive Cardiology, shared his 60-second take on the newly released AHA/ACC Cholesterol Guidelines.
A behind the scenes rough cut of a video coming soon to Mass General Advances, as our @pnatarajanmd offers his take on the new cholesterol guidelines just revealed at #AHA18: https://t.co/6Qtdetbzar via @YouTube #massgeneraladvances #MGH— Mass General Heart (@MGHHeartHealth) November 12, 2018
Results presented from the REDUCE-IT trial show cardiovascular risk reduction with icosapent ethyl, the first Pure EPA prescription Omega-3.
In the REDUCE-IT trial, which involved statin-treated patients with hypertriglyceridemia, the risk of ischemic events, including cardiovascular death, was significantly lower with 4 g of icosapent ethyl daily than with placebo. https://t.co/VcTV18TTU5 #AHA18— NEJM (@NEJM) November 10, 2018
Sawallah Guseh, MD, Wins Laennec Young Clinician Award
Mass General's own Sawallah Guseh, MD, cardiology fellow, received the Laennec Young Clinician Award, which recognizes the importance of clinical accumen, inductive analytic skills and teaching ability in future academic cardiologists.
Honored to receive the Laennec Young Clinician Award & humbled to have been considered! Enjoyed the experience & thoughtful questions. Even more, meeting the other bright finalists was inspirational & I recommend participation to all FITs!#AHA18 @MGHHeartHealth @ddefariayeh https://t.co/D9DUuOAeQI— J. Sawalla Guseh, M.D. (@goosecoid) November 13, 2018
Exercise and Regenerative Heart Activity
Anthony Rosenzweig, MD, chief of Cardiology, shared his expertise on the relationship between exercise and regenerative heart activity.
The most important aspect of PIONEER: we now know it is safe to initiate sacubitril/valsartan in acute HF. Initiating life-saving therapies in the hospital allows for better pt compliance, earlier application of a Class I agent and should improve outcomes.— James Januzzi (@JJheart_doc) November 12, 2018
Robert Levine: AHA Distinguished Scientist
Congratulations to Dr. Robert Levine @MGHHeartHealth @MGHMedicine @mghecho @ASE360— Akl Fahed (@aklfahed) November 11, 2018
AHA 2018 Distinguished Scientist #AHA18 @AHAMeetings @AHAResearch @AHAScience #AHAEarlyCareerBlogger @HeartNews pic.twitter.com/zOGU5z0ill
Mechanism Linking Noise Exposure to Metabolic Disease
Dr. Michael Osborne and Dr. Tawakol @ATawakolMD on the mechanism linking noise exposure to metabolic disease @AHAMeetings @AHA_Research @AHAScience @HeartNews @MGHHeartHealth #AHA18 pic.twitter.com/cF7rxNuFqF— Nasrien E. Ibrahim, MD (@IAmDrIbrahim) November 10, 2018
Do you use Twitter to disseminate innovative treatment approaches and new data? Tell us about your experience with social media as a platform for discussing research in the comments below.
Refer a patient to the Mass General Heart Center
Learn more about Mass General at #AHA18